Buy Score Rank #2546 out of #5176
Fri 18'th Aug 2017
Progenics Pharmaceuticals Inc. Stock Analysis
Technical stock analysis for Fri 18'th Aug 2017
Sell candidate since 2017-08-16 Loss -3.97%
Progenics Pharmaceuticals Inc. lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.69% during the next 3 months and, with 90% probability hold a price between $4.15 and $5.62 at the end of this period.
Some negative signals were issued as well, and these may have some influence on the near short-term development. Progenics Pharmaceuticals Inc. holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $6.27. On a fall, the stock will find some support from the short-term average at $5.55. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. A sales signal was issued from a pivot top point on Wednesday August 16, 2017, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Relative Strength Index (RSI)
RSI14 is 43 and the stock is currently not being overbought or oversold
Support & Resistance
Progenics Pharmaceuticals Inc. finds support from accumulated volume at $5.33. On the upside the stock meets some resistance from accumulated volume at $6.69, $6.90 and $6.95.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.22 between high and low, or 3.99%. For the last week, the stock has had a daily average volatility of 7.04%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Progenics Pharmaceuticals Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.